Addex Therapeutics Ltd(ADXN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADXN Addex Therapeutics Ltd

Market Closed 12-20 16:00:00 EST

7.90

+0.04

+0.51%

盘后8.15

+0.25+3.16%

16:00 EST

High7.90	Low7.84	Vol12.11K
Open7.84	D1 Closing7.86	Amplitude0.76%
Mkt Cap8.44M	Tradable Cap4.23M	Total Shares1.07M
T/O95.13K	T/O Rate2.26%	Tradable Shares535.10K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ADXN","market":"US","secType":"STK","nameCN":"Addex Therapeutics Ltd","latestPrice":7.9,"timestamp":1734728400000,"preClose":7.86,"halted":0,"volume":12111,"hourTrading":{"tag":"盘后","latestPrice":8.15,"preClose":7.9,"latestTime":"16:00 EST","volume":9,"amount":73.35,"timestamp":1734728402327},"delay":0,"floatShares":535100,"shares":1068900,"eps":7.477643,"marketStatus":"Market Closed","change":0.04,"latestTime":"12-20 16:00:00 EST","open":7.84,"high":7.9,"low":7.84,"amount":95132.3974,"amplitude":0.007634,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":7.477643,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1734944400000},"marketStatusCode":7,"adr":0,"adrRate":120,"exchange":"NASDAQ","adjPreClose":7.86,"postHourTrading":{"tag":"盘后","latestPrice":8.15,"preClose":7.9,"latestTime":"16:00 EST","volume":9,"amount":73.35,"timestamp":1734728402327},"volumeRatio":0.9876210955386507},"requestUrl":"/m/hq/s/ADXN","defaultTab":"news","newsList":[{"id":"2486879006","title":"Are Medical Stocks Lagging  ADMA Biologics (ADMA) This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2486879006","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486879006?lang=en_us&edition=fundamental","pubTime":"2024-11-27 22:40","pubTimestamp":1732718407,"startTime":"0","endTime":"0","summary":"The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Adma Biologics  been one of those stocks this year?Let's take a closer look at the stock's year-to-date performance to find out.Adma Biologics is a member of our Medical group, which includes 1022 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Adma Biologics is currently sporting a Zacks Rank of #2 .According to our latest data, ADMA has moved about 382.7% on a year-to-date basis. At the same time, Medical stocks have gain","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/e0VWXB5.wUFiKGuJPPpLzg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/e0VWXB5.wUFiKGuJPPpLzg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medical-stocks-lagging-adma-biologics-144007799.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADMA","BK4139","ADXN"],"gpt_icon":0},{"id":"2485278012","title":"Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Highlights: Strategic Partnerships and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2485278012","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485278012?lang=en_us&edition=fundamental","pubTime":"2024-11-23 15:01","pubTimestamp":1732345312,"startTime":"0","endTime":"0","summary":"Revenue: CHF0.1 million in Q3 2024, compared to CHF0.3 million in Q3 2023.G&A Expenses: CHF0.5 million in Q3 2024, decreased by CHF5.1 million from Q3 2023.Net Loss from Associates: CHF0.9 million related to investment in Neurosterix Group.Cash Position: CHF3.3 million as of Q3 2024.Current Liabilities: CHF0.9 million as of September 30, 2024, decreased by CHF2 million from December 31, 2023.GuruFocus has detected 6 Warning Signs with ADXN.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Addex Therapeutics Ltd  is eligible for up to USD330 million in milestone payments and tiered royalties from the partnership with Indivior.Neurosterix, a spin-out company, has made excellent progress, starting IND-enabling studies with its M4 PAM program.Q: What would be the cash autonomy for Neurosterix, considering the $63 million they have got on inception?A: Tim Dyer, CEO: Neurosterix is capitalized with $63 million in financing. Its cash burn is r","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/CGkXkhqoV4XYs96JAbl7Eg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/5b87ba10fad44b873a0cb40737b15dc3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/CGkXkhqoV4XYs96JAbl7Eg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/5b87ba10fad44b873a0cb40737b15dc3"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/addex-therapeutics-ltd-adxn-q3-070152951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADXN","INDV"],"gpt_icon":0},{"id":"2485565239","title":"Addex Therapeutics GAAP EPS of -CHF0.02, revenue of CHF0.06M","url":"https://stock-news.laohu8.com/highlight/detail?id=2485565239","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485565239?lang=en_us&edition=fundamental","pubTime":"2024-11-22 17:06","pubTimestamp":1732266375,"startTime":"0","endTime":"0","summary":"Addex Therapeutics press release  (NASDAQ:ADXN): Q3  GAAP EPS of -CHF0.02.\nIncome of CHF0.06M (-81.8% Y/Y).\nCompleted Q3, 2024 with cash and cash equivalents of CHF3.3 million.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4320135-addex-therapeutics-gaap-eps-of--chf002-revenue-of-chf006m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["ADXN","LENZ"],"gpt_icon":0},{"id":"2485283227","title":"Addex Therapeutics Reported Q3 EPS Of CHF(0.02) Up From CHF(0.03), Cash Balance Of CHF3.35M","url":"https://stock-news.laohu8.com/highlight/detail?id=2485283227","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485283227?lang=en_us&edition=fundamental","pubTime":"2024-11-22 14:14","pubTimestamp":1732256073,"startTime":"0","endTime":"0","summary":"Q3 2024 Operating Highlights:Successfully completed funded research phase of the Indivior collaboration with both Indivior and Addex each selecting GABAB PAM drug candidate for further development in SUD and chronic","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/42131162/addex-therapeutics-reported-q3-eps-of-chf-0-02-up-from-chf-0-03-cash-balance-of-chf3-35m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADXN","LENZ"],"gpt_icon":0},{"id":"2485283566","title":"Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2485283566","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485283566?lang=en_us&edition=fundamental","pubTime":"2024-11-22 14:00","pubTimestamp":1732255200,"startTime":"0","endTime":"0","summary":"Indivior selected GABA B PAM drug candidate for development in substance use disorders  and starts IND enabling studies. Geneva, Switzerland, November 22, 2024 - Addex Therapeutics , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its third quarter financial results for the periods ended September 30, 2024, and provided a corporate update.“During the third quarter of 2024, Indivior selected a GABAB PAM drug candidate from our collaboration for development in substance use disorders, allowing us to select our proprietary GABAB PAM drug candidate as a potential treatment for chronic cough. While we intend to further advance this new program in-house, we will also look for partners to fund the later clinical development stages of the program,” said Tim Dyer CEO of Addex.Successfully completed funded research phase of the Indivior collaboration with both Indivior and Addex ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/wRKQE0PUmvNEyUedzSOexw--~B/aD0xMTU7dz0yMzE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/03dc53124eb1c9b2d6a22646894f9199","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/wRKQE0PUmvNEyUedzSOexw--~B/aD0xMTU7dz0yMzE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/03dc53124eb1c9b2d6a22646894f9199"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/addex-reports-third-quarter-2024-060000979.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ADXN"],"gpt_icon":1},{"id":"2484964181","title":"Addex Therapeutics Ltd  expected to post a loss of 1 rappen a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2484964181","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484964181?lang=en_us&edition=fundamental","pubTime":"2024-11-20 19:01","pubTimestamp":1732100483,"startTime":"0","endTime":"0","summary":"Addex Therapeutics Ltd  expected to post a loss of 1rappen a share - Earnings Preview Addex Therapeutics Ltd ADXN.OQ, ADXN.O is expected to report resultson November 22 for the period ending June 30 2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nL8N3MR0RC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADXN"],"gpt_icon":0},{"id":"2482730648","title":"Are Medical Stocks Lagging  Addex Therapeutics (ADXN) This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2482730648","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482730648?lang=en_us&edition=fundamental","pubTime":"2024-11-11 22:40","pubTimestamp":1731336010,"startTime":"0","endTime":"0","summary":"The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Addex Therapeutics Ltd. Sponsored ADR  one of those stocks right now?Let's take a closer look at the stock's year-to-date performance to find out.Addex Therapeutics Ltd. Sponsored ADR is a member of the Medical sector. This group includes 1024 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Addex Therapeutics Ltd. Sponsored ADR is currently sporting a Zacks Rank of #2 .Addex Therapeutics Ltd. Sponsored ADR  : Free Stock Analysis Report","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Fs_R4sd8jCoOMib958Znmg--~B/aD02MDM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/432476d296d64c50172213c0415587c9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Fs_R4sd8jCoOMib958Znmg--~B/aD02MDM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/432476d296d64c50172213c0415587c9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medical-stocks-lagging-addex-therapeutics-144010072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ADXN","ADMA"],"gpt_icon":0},{"id":"2482022905","title":"Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2482022905","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482022905?lang=en_us&edition=fundamental","pubTime":"2024-11-11 14:00","pubTimestamp":1731304800,"startTime":"0","endTime":"0","summary":"Geneva, Switzerland, November 11, 2024 - Addex Therapeutics , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its provisional third quarter net results decreased significantly compared to the second quarter 2024.The provisional result for the third quarter of 2024 show a net loss of CHF 1.5 million compared to a net profit of CHF 12.9 million for the second quarter of 2024. The decrease of CHF 14.4 million is primarily due to the sale of part of the Addex business to Neurosterix during the second quarter of 2024, which generated a non-recurring net gain of CHF 14.0 million. Addex expects to generate quarterly losses in future.The provisional result for the nine-month period ended September 30, 2024, remains positive and amounts to a net profit of CHF 8.3 million compared to a net profit of CHF 9.8 for the six-month period ended June 30, 2024.Title: Addex Therapeut","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/wRKQE0PUmvNEyUedzSOexw--~B/aD0xMTU7dz0yMzE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/03dc53124eb1c9b2d6a22646894f9199","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/wRKQE0PUmvNEyUedzSOexw--~B/aD0xMTU7dz0yMzE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/03dc53124eb1c9b2d6a22646894f9199"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/addex-provisional-2024-third-quarter-060000097.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADXN","WRD","BK4139"],"gpt_icon":0},{"id":"2482441485","title":"Addex Therapeutics Ltd  expected to post a loss of 1 rappen a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2482441485","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482441485?lang=en_us&edition=fundamental","pubTime":"2024-11-09 00:02","pubTimestamp":1731081779,"startTime":"0","endTime":"0","summary":"Addex Therapeutics Ltd  expected to post a loss of 1rappen a share - Earnings Preview Addex Therapeutics Ltd ADXN.OQ, ADXN.O is expected to report resultson November 11 for the period ending June 30 2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nL8N3MF2B2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADXN"],"gpt_icon":0},{"id":"2478930759","title":"Are Medical Stocks Lagging  Boston Scientific (BSX) This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2478930759","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478930759?lang=en_us&edition=fundamental","pubTime":"2024-10-25 21:40","pubTimestamp":1729863609,"startTime":"0","endTime":"0","summary":"For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Boston Scientific  been one of those stocks this year?Let's take a closer look at the stock's year-to-date performance to find out.Boston Scientific is a member of our Medical group, which includes 1024 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Boston Scientific is currently sporting a Zacks Rank of #2 .Our latest available data shows that BSX has returned about 47.2% since the start of the calendar year. In comparis","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0K2vxHTAGj_tGrBqjPJ8Cg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f889276f4a638f3c7a79c0e3e6b768c1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0K2vxHTAGj_tGrBqjPJ8Cg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f889276f4a638f3c7a79c0e3e6b768c1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medical-stocks-lagging-boston-scientific-134009129.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1791710582.SGD","LU1023059063.AUD","LU0048584097.USD","LU0353189763.USD","LU0528227936.USD","LU1791710400.SGD","BK4082","BK4139","LU1804176565.USD","LU0238689110.USD","BSX","BK4581","LU2112291526.USD","LU2324357040.USD","LU2362540622.SGD","LU0187121727.USD","IE00B2B36J28.USD","BK4504","LU1989764664.SGD","BK4588","LU0950375773.USD","LU0823416689.USD","LU1291159041.SGD","ADXN","LU1989772840.SGD","LU2265009873.SGD","LU2506952097.USD","LU2506951875.HKD","LU1061106388.HKD","LU0077335932.USD","IE00BJT1NW94.SGD","LU0114720955.EUR","LU0882574055.USD","LU1983299246.USD","LU0122379950.USD","IE00BFTCPJ56.SGD","BK4585","LU1989764748.USD","IE00BJJMRZ35.SGD","LU2506952170.USD","LU2362541273.HKD","LU1718418525.SGD","LU0345769631.USD","LU0251132253.USD","LU2087625088.SGD","LU2362541513.USD","LU1989771016.USD","LU1989772923.USD","LU0266013472.USD","IE00B4R5TH58.HKD"],"gpt_icon":0},{"id":"2472226317","title":"Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript Highlights: Key Financials and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2472226317","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472226317?lang=en_us&edition=fundamental","pubTime":"2024-10-01 15:00","pubTimestamp":1727766037,"startTime":"0","endTime":"0","summary":"Series A Financing: USD 63 million led by Perceptive Advisors.Equity Interest in Neurosterix: CHF 5 million and a 20% equity interest.Milestone Payments: Up to $330 million from Indivior for GABAB PAM program.Revenue: CHF 0.1 million in Q2 2024, down from CHF 0.6 million in Q2 2023.R&D Expenses: CHF 0.3 million in Q2 2024, stable compared to Q2 2023.Cash Position: CHF 3.8 million as of June 30, 2024.Current Liabilities: CHF 0.9 million as of June 30, 2024, decreased by CHF 1.9 million compared to June 30, 2023.Non-Current Liabilities: CHF 0.1 million, decreased by CHF 5.5 million compared to December 31, 2023.GuruFocus has detected 5 Warning Signs with ADXN.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Addex Therapeutics Ltd  secured USD 63 million in Series A financing led by Perceptive Advisors, providing resources to advance their preclinical portfolio without diluting shareholders' interests.Janssen Pharmaceuticals discontinued ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/CGkXkhqoV4XYs96JAbl7Eg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/5b87ba10fad44b873a0cb40737b15dc3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/CGkXkhqoV4XYs96JAbl7Eg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/5b87ba10fad44b873a0cb40737b15dc3"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/addex-therapeutics-ltd-adxn-q2-070037120.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["INDV","ADXN"],"gpt_icon":0},{"id":"2471805894","title":"Addex Therapeutics GAAP EPS of CHF0.08, revenue of CHF0.12M","url":"https://stock-news.laohu8.com/highlight/detail?id=2471805894","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471805894?lang=en_us&edition=fundamental","pubTime":"2024-09-30 16:10","pubTimestamp":1727683856,"startTime":"0","endTime":"0","summary":"Addex Therapeutics press release  (NASDAQ:ADXN): Q2  GAAP EPS of CHF0.08.\nRevenue of CHF0.12M (-81.0% Y/Y).","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4154376-addex-therapeutics-gaap-eps-of-chf008-revenue-of-chf012m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["ADXN"],"gpt_icon":0},{"id":"2471252518","title":"Addex Therapeutics Reported Q2 EPS Of CHF0.08, Cash Balance Of CHF3.8M","url":"https://stock-news.laohu8.com/highlight/detail?id=2471252518","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471252518?lang=en_us&edition=fundamental","pubTime":"2024-09-30 14:49","pubTimestamp":1727678974,"startTime":"0","endTime":"0","summary":"Key Half Year and Q2 2024 Financial Data:CHF&#39; thousandsQ2 24Q2 23*ChangeH1 24H1 23*ChangeIncome115632(517)3501,134(784)R&amp;D expenses(339)(291)(48)(584)(547)(37)G&amp;A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/09/41085229/addex-therapeutics-reported-q2-eps-of-chf0-08-cash-balance-of-chf3-8m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADXN","LENZ"],"gpt_icon":0},{"id":"2471844214","title":"Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2471844214","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471844214?lang=en_us&edition=fundamental","pubTime":"2024-09-30 13:00","pubTimestamp":1727672400,"startTime":"0","endTime":"0","summary":"Launched Neurosterix with Perceptive Advisors to accelerate the development of M4PAM for schizophrenia. Indivior selected GABA B PAM drug candidate for development in substance use disorders. Addex selected independent GABAB PAM drug candidate for development in chronic cough. Geneva, Switzerland, September 30, 2024 - Addex Therapeutics , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its half-year and second quarter financial results for the periods ended June 30, 2024, and provided a corporate update.“During the first half, we achieved major milestones with the launch of Neurosterix with a series A financing of $63m led by Perceptive Advisors and the selection of drug candidates in our GABAB PAM collaboration with Indivior. Indivior has selected a drug candidate for further development in substance use disorder and will now take full responsibility for future develop","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/wRKQE0PUmvNEyUedzSOexw--~B/aD0xMTU7dz0yMzE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/03dc53124eb1c9b2d6a22646894f9199","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/wRKQE0PUmvNEyUedzSOexw--~B/aD0xMTU7dz0yMzE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/03dc53124eb1c9b2d6a22646894f9199"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/addex-therapeutics-reports-2024-half-050000552.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ADXN","LENZ"],"gpt_icon":0},{"id":"2468503086","title":"Addex Therapeutics reports H1 results","url":"https://stock-news.laohu8.com/highlight/detail?id=2468503086","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468503086?lang=en_us&edition=fundamental","pubTime":"2024-09-19 22:35","pubTimestamp":1726756516,"startTime":"0","endTime":"0","summary":"Addex Therapeutics press release  (NASDAQ:ADXN): H1 net gain of CHF 9.8 million.\nThe cash position of the Group amounted to CHF 3.8 million as of June 30, 2024.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4151197-addex-therapeutics-reports-h1-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["NQmain","PSQ","ADXN","MNQmain","SQQQ","QLD","TQQQ","BK4139","LENZ","QID",".IXIC"],"gpt_icon":0},{"id":"2468651129","title":"Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2468651129","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468651129?lang=en_us&edition=fundamental","pubTime":"2024-09-19 13:00","pubTimestamp":1726722000,"startTime":"0","endTime":"0","summary":"Geneva, Switzerland, September 19, 2024 - Addex Therapeutics , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its provisional half-year and second quarter net results have increased significantly in 2024 compared to 2023 and first quarter 2024 results primarily due to the sale of part of its business to Neurosterix Pharma Sàrl on April 2, 2024.We will issue our Half-Year 2024 Financial Results on September 30, 2024. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST  the same day.Title: Addex Therapeutics Half-Year 2024 financial results and corporate update Date: September 30, 2024Time: 16:00 CEST ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/wRKQE0PUmvNEyUedzSOexw--~B/aD0xMTU7dz0yMzE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/03dc53124eb1c9b2d6a22646894f9199","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/wRKQE0PUmvNEyUedzSOexw--~B/aD0xMTU7dz0yMzE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/03dc53124eb1c9b2d6a22646894f9199"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/addex-provisional-2024-half-second-050000122.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ADXN"],"gpt_icon":0},{"id":"2465761913","title":"Are Medical Stocks Lagging  Addex Therapeutics (ADXN) This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2465761913","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2465761913?lang=en_us&edition=fundamental","pubTime":"2024-09-06 21:40","pubTimestamp":1725630011,"startTime":"0","endTime":"0","summary":"Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Addex Therapeutics Ltd. Sponsored ADR  been one of those stocks this year?A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Addex Therapeutics Ltd. Sponsored ADR is one of 1019 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Addex Therapeutics Ltd. Sponsored ADR is currently sporting a Zacks Rank of #2 .","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/F3nzpi36wi9juoO_v9PrEA--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/2a50596f066181e48e4ae0ad6be00462","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/F3nzpi36wi9juoO_v9PrEA--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/2a50596f066181e48e4ae0ad6be00462"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medical-stocks-lagging-addex-therapeutics-134011189.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0114720955.EUR","LU2324357040.USD","BK4082","LU0267386448.USD","IE00BJT1NW94.SGD","LU2491050071.SGD","LU1718418525.SGD","BK4504","LU2087625088.SGD","LU2362541513.USD","LU2491050154.USD","BSX","LU0077335932.USD","LU1061106388.HKD","LU1983299246.USD","LU2506952097.USD","LU1791710400.SGD","BK4585","LU2244417387.USD","LU0266013472.USD","LU2265009873.SGD","LU2362541273.HKD","LU2506951958.HKD","LU2362540622.SGD","LU0353189763.USD","LU0823417737.USD","LU1023059063.AUD","LU2112291526.USD","LU0011850046.USD","LU0950375773.USD","LU0823416689.USD","IE0009355771.USD","LU1804176565.USD","LU1791710582.SGD","LU1057294990.SGD","LU0823417653.USD","LU0353189680.USD","IE00BFTCPJ56.SGD","LU2491049909.HKD","LU2506951875.HKD","IE00BJJMRZ35.SGD","LU0528227936.USD","IE0002141913.USD","LU0238689110.USD","ADXN","BK4581","LU0882574055.USD","LU0187121727.USD","BK4588","LU1291159041.SGD"],"gpt_icon":0},{"id":"2463496525","title":"Addex Stock Soars on Crucial Update From Indivior Research Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2463496525","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463496525?lang=en_us&edition=fundamental","pubTime":"2024-08-28 22:30","pubTimestamp":1724855400,"startTime":"0","endTime":"0","summary":"Per the press release, Indivior has chosen a compound for future development in treating substance use disorder and will manage all further development efforts. Under the terms of the existing agreement, Addex is eligible to receive up to $330 million if certain regulatory, clinical and commercial milestones are met, along with tiered royalties on net sales from INDV, ranging from high single digits to low double digits. Subject to successful development, such payments will aid ADXN in strengthening in cash position as it continues to build its portfolio of novel treatments for neurological disorders.Year to date, shares of Addex have rallied 91.4% against the industry’s 1% decline.Indivior stated that the distinguished mechanism of its selected substance use disorder treatment candidate could help overcome the complex challenges in this field to potentially develop new therapies. INDV expects to begin investigational new drug application  enabling studies of the candidate in the first","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/addex-stock-soars-crucial-indivior-143000320.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["JNJ","LU0792757196.USD","LU1430594728.SGD","BK4139","SG9999001440.SGD","LU0345770993.USD","LU1221951046.USD","IE00B1BXHZ80.USD","LU1221951129.SGD","LU2133065610.SGD","LU1032466523.USD","BK4592","LU1162221912.USD","BK4563","LU1585245621.USD","PAM","LU0795875086.SGD","LU1261432733.SGD","BK4581","LU1057294990.SGD","FULC","IE0002270589.USD","LU1929549753.HKD","LU0640476718.USD","BK4081","BK4532","LU1244550577.SGD","BK4534","IE00B19Z3581.USD","LU0466842654.USD","LU1732800096.USD","LU2347655156.SGD","LU1244550494.USD","LU2468319806.SGD","ADXN","LU0912757837.SGD","LU1196500208.SGD","LU2602419157.SGD","BK4588","IE00BSNM7G36.USD","INDV","LU0345770308.USD","LU1059921491.USD","LU1032955483.USD","LU0234572021.USD","LU1023059063.AUD","BK4504","LU1267930813.SGD","BK4585","LU0889566641.SGD"],"gpt_icon":0},{"id":"2462546378","title":"Clinical Collaboration Ignites Addex Therapeutics (ADXN) Stock Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=2462546378","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462546378?lang=en_us&edition=fundamental","pubTime":"2024-08-28 21:21","pubTimestamp":1724851304,"startTime":"0","endTime":"0","summary":"Shares of Addex Therapeutics ($ADXN) have rallied in the past few days, soaring by 43%, after the company announced the selection of clinical candi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/clinical-collaboration-ignites-addex-therapeutics-adxn-stock-rally?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/clinical-collaboration-ignites-addex-therapeutics-adxn-stock-rally?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ADXN"],"gpt_icon":0},{"id":"2462453288","title":"Addex Therapeutics Price Target Maintained With a $30.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2462453288","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462453288?lang=en_us&edition=fundamental","pubTime":"2024-08-28 19:01","pubTimestamp":1724842860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADXN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 28, 2024 07:01 ET (11:01 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADXN","LENZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.addextherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0125},{"period":"1month","weight":0.0705},{"period":"3month","weight":-0.1972},{"period":"6month","weight":-0.0094},{"period":"1year","weight":0.3908},{"period":"ytd","weight":0.3058}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.280617},{"month":2,"riseRate":0.2,"avgChangeRate":0.117741},{"month":3,"riseRate":0.2,"avgChangeRate":-0.133163},{"month":4,"riseRate":0.4,"avgChangeRate":-0.114175},{"month":5,"riseRate":0.2,"avgChangeRate":-0.060298},{"month":6,"riseRate":0.4,"avgChangeRate":-0.143331},{"month":7,"riseRate":0.8,"avgChangeRate":0.034171},{"month":8,"riseRate":0.4,"avgChangeRate":0.138908},{"month":9,"riseRate":0,"avgChangeRate":-0.158047},{"month":10,"riseRate":0.2,"avgChangeRate":-0.069255},{"month":11,"riseRate":0,"avgChangeRate":-0.108501},{"month":12,"riseRate":0.4,"avgChangeRate":0.016309}],"exchange":"NASDAQ","name":"Addex Therapeutics Ltd","nameEN":"Addex Therapeutics Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Addex Therapeutics Ltd(ADXN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Addex Therapeutics Ltd(ADXN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Addex Therapeutics Ltd,ADXN,Addex Therapeutics Ltd股票,Addex Therapeutics Ltd股票老虎,Addex Therapeutics Ltd股票老虎国际,Addex Therapeutics Ltd行情,Addex Therapeutics Ltd股票行情,Addex Therapeutics Ltd股价,Addex Therapeutics Ltd股市,Addex Therapeutics Ltd股票价格,Addex Therapeutics Ltd股票交易,Addex Therapeutics Ltd股票购买,Addex Therapeutics Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Addex Therapeutics Ltd(ADXN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Addex Therapeutics Ltd(ADXN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction